Effects of streptozotocin-induced diabetes on feeding stimulated by centrally administered opioid agonists

Blake A. Gosnell, Martha Grace, Charles J. Billington, Allen S. Levine

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

The potencies of several opioid agonists are reduced in diabetic animals and in animals made hyperglycemic via injections of glucose. In this report we examined the effects of streptozotocin-induced diabetes on the feeding responses to centrally administered opioid agonists with differing receptor selectivities. The selective mu receptor agonist Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAGO) caused a larger increase in intake in diabetic rats than in controls. In both groups feeding responses were greater on the fourth day of daily injections than on the first day. The delta receptor agonist [D-Ser2,Leu5]-enkephalin-Thr6 (DSLET) stimulated intake in controls but not in diabetics. However, the elevated baseline and large variability in intake of the diabetics in this experiment prevent drawing a conclusion on diabetes-induced changes in the potency of this peptide. No differences between controls and diabetics were apparent in the feeding responses to U50,488H, a selective kappa receptor agonist. These data suggest that diabetes may differentially affect the classes of opioid receptors or the binding of ligands to these receptors.

Original languageEnglish (US)
Pages (from-to)31-40
Number of pages10
JournalLife Sciences
Volume45
Issue number1
DOIs
StatePublished - 1989
Externally publishedYes

Bibliographical note

Funding Information:
This research was supported by the National Institute on Drug Abuse (DA 03999), the National Institutes of Health (NS 23565) and the Veterans Administration.

Fingerprint Dive into the research topics of 'Effects of streptozotocin-induced diabetes on feeding stimulated by centrally administered opioid agonists'. Together they form a unique fingerprint.

Cite this